Personal Genome Services Market Report 2026

Personal Genome Services Market Overview

• Personal Genome Services market size has reached to $6.84 billion in 2025 • Expected to grow to $13.69 billion in 2030 at a compound annual growth rate (CAGR) of 14.9% • Growth Driver: Rising Focus On Personalised Medicine Drives The Market Growth Due To Advances In Genomics And Tailored Therapeutics • Market Trend: Innovations In Personal Genome Services Enhance Risk Prediction And Preventive Care In Prostate Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Personal Genome Services Market?

Personal genome services refer to direct-to-consumer or clinical services that analyze an individual’s complete or partial genetic makeup using genomic sequencing and bioinformatics tools to provide insights into health risks, inherited traits, disease predisposition, drug response, ancestry, and personalized wellness recommendations. These services help individuals and healthcare providers make informed decisions about preventive care, lifestyle changes, medical treatments, and family planning based on a person’s unique genetic profile. The main service types of personal genome services are genetic testing, whole genome sequencing, carrier testing, ancestry testing, and other service types. Genetic Testing refers to services that analyze an individual’s DNA to identify genetic variations linked to health, traits, or ancestry. These services are used across multiple applications, including healthcare, research, ancestry, and other applications, and cater to various end-users, such as hospitals and clinics, research centers, direct-to-consumer, and other end-users.

What Is The Personal Genome Services Market Growth Forecast?

The personal genome services market size is expected to see rapid growth in the next few years. It will grow to $13.69 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to growth in preventive genomics adoption, expansion of pharmacogenomics usage, rising personalized wellness demand, broader insurance supported testing, integration with digital health platforms. Major trends in the forecast period include direct to consumer genome testing, integrated health risk genomic reports, pharmacogenomic service bundles, preventive genome screening packages, digital genetic counseling platforms.

What Is The Driver Of The Personal Genome Services Market?

The increasing focus on Personalized Medicine is expected to propel the growth of the personal genome services market going forward. Personalized medicine is a medical approach that customizes treatment and prevention strategies based on an individual’s genetic, biological, and lifestyle characteristics. The adoption of personalized medicine is increasing due to advances in genomics and molecular diagnostics, which allow treatments to be tailored to an individual’s genetic profile for better outcomes. Personal genome services enable personalized medicine by analyzing an individual’s genetic makeup to predict disease risk, guide drug selection, and tailor prevention and treatment strategies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing focus on personalized medicine is driving the growth of the personal genome services industry.

Key Players In The Global Personal Genome Services Market

Major companies operating in the personal genome services market are Thermo Fisher Scientific Inc, Illumina Inc, Helix OpCo LLC, Ancestry.com Operations Inc, Fulgent Genetics Inc, 23andMe Holding Co, Prenetics Global Limited, MyHeritage Ltd, Color Health Inc, Genomics plc, GenoPalate Inc, Living DNA Ltd, Mapmygenome India Pvt Ltd, Nebula Genomics Inc, Xcode Life Sciences Pvt Ltd, Sema4 Holdings Corp, Gene by Gene Ltd, TellmeGen SL, CRI Genetics LLC, African Ancestry Inc, and DNAFit Limited.

Global Personal Genome Services Market Trends and Insights

Major companies operating in the personal genome services market are focusing on developing advanced solutions such as genome-wide risk stratification to provide personalized health insights, predict disease susceptibility, and guide preventive and lifestyle interventions. Genome-wide risk stratification refers to the process of analyzing an individual’s entire genome to identify genetic variations that contribute to the risk of developing certain diseases or conditions, enabling personalized predictions of health risks and targeted preventive strategies. For instance, in November 2025, MyOme Inc., a US-based biotechnology company, launched the first integrated polygenic risk score (iPRS) test for prostate cancer. It combines ~7 million genetic markers with clinical factors to deliver personalized 10-year and lifetime risk estimates, validated in 140,000+ diverse men. Its purpose is early detection and prevention for 95% of cases without rare variants such as BRCA2, guiding PSA or MRI or biopsies for high-risk individuals (3-4x elevated odds in top decile) while cutting false positives and overtreatment. Benefits include precise stratification, equitable performance across ancestries, and lifelong AI-updated insights from one whole-genome sample.

What Are Latest Mergers And Acquisitions In The Personal Genome Services Market?

In March 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics Corp. for an undisclosed amount. With this acquisition, Tempus AI aims to strengthen its precision medicine platform by integrating Ambry Genetics' expertise in hereditary cancer screening, pediatrics, rare diseases, immunology, reproductive health, and cardiology with its AI capabilities to capture patients early, support treatments, monitor progression, and drive clinical innovation. Ambry Genetics Corp. is a US-based company specializing in clinical genetic testing services, including hereditary cancer, rare disease, and personalized genomic insights.

What Defines the Personal Genome Services Market?

The personal genome services market includes revenues earned by entities through genetic testing services, whole genome sequencing services, exome sequencing services, ancestry analysis services, health risk assessment services, carrier screening services, pharmacogenomic testing services, wellness reporting services, trait analysis services, and personalized nutrition recommendations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Personal Genome Services Market Report 2026?

The personal genome services market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the personal genome services industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.